Currently PD-1/PD-L1 inhibitors approved for the treatment of HCC include sindilizumab, karelizumab, atezolizumab, durvalumab, etc. CTLA-4 inhibitors include terelizumab, and these inhibitors have been shown to be effective in some patients with advanced HCC (18). Here, CD274 is linked to hepatocellular carcinoma.